GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (NAS:VRDN) » Definitions » Cyclically Adjusted PB Ratio

Viridian Therapeutics (Viridian Therapeutics) Cyclically Adjusted PB Ratio : 0.11 (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Viridian Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-05), Viridian Therapeutics's current share price is $11.60. Viridian Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $105.45. Viridian Therapeutics's Cyclically Adjusted PB Ratio for today is 0.11.

The historical rank and industry rank for Viridian Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

VRDN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.11   Med: 0.31   Max: 0.6
Current: 0.11

During the past years, Viridian Therapeutics's highest Cyclically Adjusted PB Ratio was 0.60. The lowest was 0.11. And the median was 0.31.

VRDN's Cyclically Adjusted PB Ratio is ranked better than
86.59% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs VRDN: 0.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Viridian Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $6.000. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $105.45 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Viridian Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Viridian Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics Cyclically Adjusted PB Ratio Chart

Viridian Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.47 0.20

Viridian Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.39 0.26 0.20 0.17

Competitive Comparison of Viridian Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Viridian Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viridian Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's Cyclically Adjusted PB Ratio falls into.



Viridian Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Viridian Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=11.60/105.45
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Viridian Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6/131.7762*131.7762
=6.000

Current CPI (Mar. 2024) = 131.7762.

Viridian Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 503.450 100.560 659.736
201409 447.948 100.428 587.774
201412 356.395 99.070 474.054
201503 394.155 99.621 521.378
201506 313.823 100.684 410.735
201509 267.252 100.392 350.801
201512 220.224 99.792 290.807
201603 175.189 100.470 229.777
201606 134.384 101.688 174.146
201609 97.706 101.861 126.401
201612 -6.587 101.863 -8.521
201703 33.638 102.862 43.093
201706 28.861 103.349 36.799
201709 26.718 104.136 33.810
201712 25.596 104.011 32.429
201803 36.128 105.290 45.216
201806 33.176 106.317 41.121
201809 29.538 106.507 36.546
201812 24.973 105.998 31.046
201903 19.868 107.251 24.411
201906 16.160 108.070 19.705
201909 11.145 108.329 13.557
201912 6.778 108.420 8.238
202003 7.630 108.902 9.233
202006 5.983 108.767 7.249
202009 5.530 109.815 6.636
202012 -14.361 109.897 -17.220
202103 -7.605 111.754 -8.968
202106 -6.441 114.631 -7.404
202109 2.226 115.734 2.535
202112 2.252 117.630 2.523
202203 2.007 121.301 2.180
202206 1.350 125.017 1.423
202209 6.631 125.227 6.978
202212 6.123 125.222 6.443
202303 5.008 127.348 5.182
202306 4.154 128.729 4.252
202309 3.402 129.860 3.452
202312 4.362 129.419 4.441
202403 6.000 131.776 6.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Viridian Therapeutics  (NAS:VRDN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Viridian Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viridian Therapeutics (Viridian Therapeutics) Business Description

Traded in Other Exchanges
Address
221 Crescent Street, Suite 401, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Executives
Stephen F. Mahoney director, officer: President and CEO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham officer: Chief Operating Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sarah Gheuens director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Seth Harmon officer: See Remarks C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453
Lara Meisner officer: General Counsel and Secretary C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453
Scott Dunseth Myers director, officer: Chief Executive Officer C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Jonathan Violin officer: President and COO 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Barrett Katz officer: Chief Medical Officer 6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301
Fairmount Healthcare Fund Gp Llc director, other: See Remarks 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Carrie Melvin officer: COO C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453
Frazier Life Sciences Public Fund, L.p. 10 percent owner TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101
L.p. Fhmlsp, 10 percent owner C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Fhmlsp, L.l.c. 10 percent owner C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Kristian Humer officer: CFO and CBO C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jennifer K. Moses director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709